Pimavanserin + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
72
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Adjunctive Treatment of Major Depressive Disorder
Conditions
Adjunctive Treatment of Major Depressive Disorder
Trial Timeline
Apr 25, 2019 → May 29, 2020
NCT ID
NCT03968159About Pimavanserin + Placebo
Pimavanserin + Placebo is a phase 3 stage product being developed by Acadia Pharmaceuticals for Adjunctive Treatment of Major Depressive Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT03968159. Target conditions include Adjunctive Treatment of Major Depressive Disorder.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05523895 | Phase 2/3 | Completed |
| NCT04531982 | Phase 3 | Completed |
| NCT03968159 | Phase 3 | Completed |
| NCT03575052 | Phase 3 | Completed |
| NCT02970305 | Phase 2 | Completed |
| NCT02970292 | Phase 3 | Completed |
Competing Products
2 competing products in Adjunctive Treatment of Major Depressive Disorder
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Pimavanserin | Acadia Pharmaceuticals | Phase 2 | 47 |
| Pimavanserin | Acadia Pharmaceuticals | Phase 3 | 72 |